Apyx Medical Co. (NASDAQ:APYX) Short Interest Update

Apyx Medical Co. (NASDAQ:APYX) was the target of a large decline in short interest in November. As of November 30th, there was short interest totalling 120,000 shares, a decline of 14.6% from the November 15th total of 140,500 shares. Currently, 0.4% of the company’s stock are short sold. Based on an average daily trading volume, of 51,300 shares, the days-to-cover ratio is presently 2.3 days.

Apyx Medical Stock Down 0.6 %

APYX opened at $1.68 on Monday. The firm has a market cap of $63.24 million, a P/E ratio of -2.02 and a beta of 1.27. The company has a debt-to-equity ratio of 3.03, a quick ratio of 4.52 and a current ratio of 5.46. The business has a 50 day moving average price of $1.37 and a 200 day moving average price of $1.33. Apyx Medical has a twelve month low of $0.97 and a twelve month high of $2.80.

Apyx Medical (NASDAQ:APYX) last posted its quarterly earnings data on Friday, November 8th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.01. The business had revenue of $11.49 million during the quarter, compared to the consensus estimate of $11.66 million. Apyx Medical had a negative net margin of 58.59% and a negative return on equity of 137.98%. During the same period in the prior year, the firm earned ($0.13) EPS. Research analysts forecast that Apyx Medical will post -0.68 EPS for the current year.

Hedge Funds Weigh In On Apyx Medical

Institutional investors have recently made changes to their positions in the business. Private Advisor Group LLC grew its holdings in Apyx Medical by 3.9% in the 3rd quarter. Private Advisor Group LLC now owns 322,321 shares of the company’s stock valued at $400,000 after buying an additional 12,180 shares during the last quarter. Commonwealth Equity Services LLC grew its stake in shares of Apyx Medical by 2.9% in the second quarter. Commonwealth Equity Services LLC now owns 511,561 shares of the company’s stock worth $685,000 after acquiring an additional 14,481 shares during the last quarter. RPg Family Wealth Advisory LLC bought a new position in Apyx Medical during the second quarter worth $101,000. Royce & Associates LP raised its stake in Apyx Medical by 3.4% during the 3rd quarter. Royce & Associates LP now owns 2,582,490 shares of the company’s stock valued at $3,202,000 after purchasing an additional 85,267 shares during the last quarter. Finally, Rathbones Group PLC boosted its holdings in Apyx Medical by 148.0% in the 2nd quarter. Rathbones Group PLC now owns 251,334 shares of the company’s stock valued at $337,000 after purchasing an additional 150,000 shares during the period. 55.33% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on APYX. BTIG Research started coverage on shares of Apyx Medical in a research report on Thursday, October 17th. They set a “neutral” rating on the stock. JMP Securities restated a “market perform” rating on shares of Apyx Medical in a report on Monday, September 16th. Finally, Craig Hallum raised shares of Apyx Medical to a “strong-buy” rating in a research report on Thursday, October 24th.

Apyx Medical Company Profile

Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures.